Rejected from Blood? The 7 Best Journals to Submit Next

Complete stories with mechanistic depth. Blood consistently favors papers that don't just describe a phenomenon but explain why it happens at the molecular or cellular level. A paper showing that a new drug works in AML is less interesting to Blood's editors than a paper showing that the drug works and explaining exactly which molecular pathway it disrupts, with functional validation.

Clinical hematology with immediate practice relevance. For clinical papers, Blood asks the same question as JCO does for oncology: will this change how hematologists manage patients? Large clinical trials, survival analyses, and treatment comparisons are evaluated against this standard.

Novel cell biology of blood cells. Blood publishes outstanding basic science about hematopoietic stem cells, red blood cell biology, platelet function, and immune cell development. If your paper reveals something genuinely new about how blood cells develop, function, or malfunction, the basic science editors will be interested.

• "The findings are confirmatory." You demonstrated something the hematology community already suspected. Blood has limited space, and confirmatory research competes poorly against papers that reveal new biology or challenge existing assumptions.

• "The clinical data is promising but preliminary." Small phase II trials, pilot studies, and single-arm clinical reports often receive this feedback. Blood wants to see either large randomized data or such striking response rates that the clinical significance is undeniable.

• "The mechanistic component is incomplete." You identified an interesting hematologic phenomenon but stopped short of explaining the underlying mechanism. Blood's reviewers will often tell you exactly which additional experiments they want to see, usually involving genetic knockdown, knockout models, or functional assays.

• "This work is better suited to a subspecialty journal." Transfusion medicine, coagulation disorders, and rare hematologic conditions compete for limited space against leukemia, lymphoma, and myeloma papers. If your paper is about a niche hematology topic, a focused journal may serve it better.

• "Overlap with recently published work." The hematology community is smaller than oncology or cardiology, and duplicate discoveries are more common. If another group published similar findings recently, Blood's editors may feel the novelty has been diminished, even if your work was conducted independently.

Before choosing your next journal, a Blood manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

1. Blood Advances

Blood Advances is Blood's companion journal, launched by ASH to provide a high-quality venue for hematology research that doesn't quite make it into Blood itself. The journal has grown rapidly in reputation and now has an IF around 7. It publishes across all hematology subspecialties and uses many of the same reviewers as Blood.

If Blood's editors suggest a transfer to Blood Advances, take it seriously. The transfer preserves your reviewer reports, so you don't start the review process over. Blood Advances is open access, which means an APC ($3,500), but your paper will be freely accessible to the global hematology community.

Best for: Broad hematology research that was competitive at Blood but didn't make the final cut, any hematology subspecialty.

2. Leukemia

Leukemia (Springer Nature) is the premier journal for hematologic malignancies and has an IF around 12. The journal publishes research on leukemia, lymphoma, myeloma, and myelodysplastic syndromes, with particular strength in molecular characterization, targeted therapies, and translational research.

If Blood rejected your malignant hematology paper, Leukemia is often the better alternative than Blood Advances because of its higher IF and focused readership. Leukemia's editors value mechanistic insights into malignant hematopoiesis, and the journal publishes strong translational work alongside clinical data.

Best for: Leukemia biology, lymphoma, myeloma, MDS, hematologic malignancy translational research, targeted therapy.

3. Haematologica

Haematologica is the journal of the European Hematology Association and serves as Blood's European counterpart. The journal has an IF around 10, publishes across all hematology subspecialties, and provides free open access (no APC for authors, funded by the EHA).

For European hematology research, or for papers with European cohort data, Haematologica is an excellent fit. The journal's editorial perspective values both basic and clinical hematology, and the no-APC model makes it particularly attractive for research groups without large publication budgets.

Best for: European hematology research, all hematology subspecialties, basic and translational hematology.

4. Journal of Clinical Oncology

For clinical hematology-oncology papers, particularly those involving treatment trials for hematologic malignancies, JCO is a legitimate alternative to Blood. JCO publishes landmark clinical trials in leukemia, lymphoma, and myeloma, especially when the results are practice-changing.

The trade-off is that JCO's readership is primarily oncologists, not hematologists, so the paper needs to be accessible to a broader clinical audience. If your paper includes detailed molecular hematology that's central to the story, JCO's editors may find it too specialized. But if the clinical message stands on its own, JCO is worth considering.

Best for: Practice-changing hematology-oncology trials, large survival analyses, clinical treatment comparisons.

5. American Journal of Hematology

AJH is a well-regarded clinical hematology journal with a fast turnaround time. The journal publishes research articles, rapid communications, and reviews across both malignant and benign hematology. If speed matters to you, AJH typically provides initial decisions in four to six weeks, which is faster than most alternatives.

AJH also publishes excellent clinical case series and retrospective analyses in hematology, making it a good option for clinical data that Blood found too preliminary or too retrospective for its standards.

Best for: Clinical hematology, rapid communications, benign hematology, retrospective clinical analyses.

6. British Journal of Haematology

BJH is a long-established hematology journal with broad scope covering both basic and clinical hematology research. The journal publishes research from all hematology subspecialties and is particularly strong in hemoglobinopathies, iron disorders, and transfusion medicine, areas that compete for limited space at Blood.

For papers in benign hematology, transfusion science, or hemoglobin disorders, BJH often provides a better editorial match than Blood or Leukemia. The journal's acceptance rate (around 25%) is higher than Blood's, and the review process is thorough without being excessively lengthy.

Best for: Benign hematology, hemoglobinopathies, iron metabolism, transfusion medicine, broad hematology research.

7. Journal of Thrombosis and Haemostasis

For coagulation and thrombosis research specifically, JTH is the dedicated venue. The journal covers hemostasis, thrombosis, vascular biology, and platelet disorders. If Blood rejected your coagulation or thrombosis paper because it was "too specialized" or competing against malignant hematology papers for space, JTH's focused readership is exactly the audience you want.

JTH is published by the ISTH (International Society on Thrombosis and Haemostasis) and carries strong recognition in the coagulation community. The journal publishes both clinical and basic research in hemostasis.

Best for: Thrombosis, hemostasis, platelet biology, coagulation disorders, anticoagulant therapy, vascular hemostasis.

Malignant hematology paper rejected? Leukemia first (higher IF than Blood Advances for malignant hematology specifically), then Blood Advances. If those pass, Haematologica and American Journal of Hematology are strong mid-tier options.

Benign hematology paper rejected? Blood Advances (same readership, broader acceptance), then BJH or AJH depending on whether the paper has a European or American focus.

Coagulation/thrombosis paper rejected? Journal of Thrombosis and Haemostasis is the dedicated venue and should be your first alternative. Don't waste time sending a coagulation paper to Leukemia or other malignant hematology journals.

Clinical trial in hematology-oncology? JCO if the trial is practice-changing. Annals of Oncology for European data. Lancet Haematology for global clinical hematology evidence.

Basic hematology science rejected? Haematologica values basic hematology and doesn't charge APCs. Experimental Hematology is another focused option for stem cell biology and hematopoiesis.

Close the mechanistic loop. Blood's reviewers frequently ask for additional functional experiments. If they requested CRISPR knockouts, patient-derived xenografts, or specific signaling pathway analyses, decide whether you can do these experiments or whether you should submit to a journal that values your current data level.

Strengthen the clinical framing for clinical papers. If your hematology trial was rejected for "preliminary data," consider combining your single-center data with data from collaborating institutions. Multi-center hematology studies are substantially more competitive at every journal in this field.

Differentiate from recent publications. If Blood noted overlap with recently published work, your resubmission must make the differentiation explicit. What does your paper show that the recently published study doesn't? Lead with the differences, not the similarities.

Consider the right word count. Blood has a strict word limit, and many authors lose content during the trimming process. When you resubmit to a journal with a different word limit, take the opportunity to restore important context that was cut. Don't submit a truncated version of a Blood-formatted paper to a journal that allows more space.

Hematology is a tight-knit field, and papers often cycle through the same set of reviewers regardless of which journal you submit to. That makes it especially important to address feedback thoroughly before your next submission. Run your revised manuscript through a manuscript scope and readiness check to check scope alignment, formatting, and structural completeness. Getting the journal match right the first time matters more in a small field where reviewer overlap is high.

Resubmit to the same tier if:

• Reviewers praised the science but identified fixable issues
• The rejection letter mentioned "consider resubmission after revision"
• You can address every concern within 2-3 months
• No competing paper has appeared since your submission

Move to a different journal if:

• The rejection cited scope mismatch, not quality
• Multiple reviewers questioned novelty or significance
• Your timeline needs a decision within 2-3 months
• A specialist journal's readership would value the work more

Reframe before resubmitting anywhere if:

• Reviewers found fundamental methodology concerns
• The narrative needs restructuring, not just polishing
• New experiments or analyses are needed
• The rejection exposed a gap between claims and evidence

In our pre-submission review work with manuscripts targeting Blood, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Mechanistic incompleteness in hematology studies. Blood's editorial standard requires that the mechanism underlying a hematological finding be fully characterized, not proposed. We see this failure as the most common pattern in Blood desk rejections we review: papers demonstrating a new drug target, transcription factor, or signaling pathway in a blood malignancy or hematopoietic context where the causal chain of events is shown incompletely. In our review of Blood submissions, we find that editors consistently require both the molecular mechanism and its direct relevance to hematopoiesis or hematological disease before the paper clears the desk.

Confirmatory findings without new mechanistic insight. Blood publishes advances, not confirmations. Papers demonstrating that a previously identified target behaves as expected in a new disease subtype, or that a known signaling pathway operates in a second hematological malignancy, face consistent scope redirects. We see this pattern in Blood submissions we review address questions the hematology field has already answered, with the new study adding validation rather than insight.

Phase II clinical data without accompanying mechanistic characterization. Blood applies a stricter translational standard than most hematology journals: clinical data is publishable only when the biological mechanism of the treatment effect is simultaneously characterized. Papers presenting early-phase trial results, biomarker correlations, or outcome data without explaining why the treatment works consistently fail at the desk. We see this failure pattern regularly in manuscripts we review for Blood with compelling efficacy signals but no mechanistic story.

Single-cell or omics profiling without functional follow-up of the key discoveries. Blood editors expect that high-dimensional discovery data generate hypotheses that are then tested experimentally. We see this pattern in Blood submissions we review: comprehensive single-cell RNA-seq atlases, proteomics datasets, or ATAC-seq maps of hematopoietic cells where the top discoveries are ranked and reported without functional validation of the most important hits.

SciRev community data for Blood confirms desk rejections typically arrive within days, with post-review first decisions within 4-6 weeks, consistent with the fast editorial cadence the American Society of Hematology maintains.